Non-invasive Assessment of Liver Fibrosis in a French Cohort of Pediatric Patients With Type III Glycogen Storage Disease: Current State and Perspectives

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-21
SponsorUniversity Hospital, Strasbourg, France

About this trial

Patients with type III glycogen storage disease (GSDIII) can develop liver fibrosis, which can be complicated by liver failure or even hepatocellular carcinoma. Since the beginning of the 21st century, non-invasive techniques for assessing fibrosis, such as liver elastography, have been developed. These techniques often make it possible to avoid liver biopsies during patient follow-up and have already been validated in the management of several diseases in adults. These techniques are also beginning to be recommended for monitoring certain chronic liver diseases in children.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Minors: from birth to 17 years

Adults: 18 to 21 years

Subjects being monitored for type III glycogen storage disease and having had at least one liver elastography measurement during their follow-up.

Disqualifiers

None

Trial population

Patients under 22 years of age

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Liver elastography values

Liver fibrosis is classified into four stages, from 0 to 4: * F0 corresponds to the absence of fibrosis * F4 corresponds to established cirrhosis.

Time frame
1 hour after consultation

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.